Since the administration of quinidine (an inhibitor of CYP2D6) results in a loss of efficacy with MK422, it is likely that the activity of this drug resides with its metabolite. Therefore, these data suggest that MK422 is a prodrug.

Return to Test Your Knowledge questions.